Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
drugs
5
×
life sciences
national blog main
alnylam pharmaceuticals
boston top stories
clinical trials
boston
new york blog main
new york top stories
onpattro
patisiran
rna interference
akcea therapeutics
aminolevulinic acid
fda
givosiran
inotersen
national top stories
new york
pfizer
san diego blog main
san diego top stories
tafamidis
accelerated approval
acute hepatic porphyria
acute hepatic porphyrias
akin akinc
alirocumab
amgen
anylam pharmaceuticals
biotech
cardiomyopathy
european medicines agency
evercore isi
evolocumab
harvard pilgrim health care
heart attack
hereditary transthyretin amyloidosis
inclisiran
What
alnylam
5
×
drug
5
×
rna
fda
interference
medicine
pharmaceuticals
rnai
ago
data
medicines
new
second
seek
speedy
akcea
amyloidosis
approval
approved
approves
attr
available
based
battle
cells
cholesterol
cleared
debilitating
disease
ema
employ
europe
evidence
far
follows
gene
genetic
harmful
heart
hits
Language
Current search:
alnylam
×
drugs
×
drug
×
@xconomy.com
4 years ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms
@xconomy.com
4 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug